Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas

Bartolomeo Merola, Annamaria Colao, Diego Ferone, Antonello Selleri, Antonella Di Sarno, Paolo Marzullo, Bernadette Biondi, Renato Spazinate, Emanuela Rossi, Gaetano Lombardi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The effects of a chronic treatment with octreotide were evaluated in 19 patients affected with functionless pituitary adenomas. Octreotide caused a significant decrease of GH and IGF-I levels in all the patients and no significant change in thyroid, adrenal and gonadal function. In contrast, during the therapy, the glucose response to an oral glucose tolerance test considerably increased and was delayed, while the insulin response decreased and was delayed. Serum a-subunit (α-SU) was above normal in 10 of 16 patients in which this evaluation was performed: octreotide caused a significant decrease (p <0.01) of a-SU levels in 6 of these 10 patients. Octreotide did not induce any significant change in visual fields except in 1 patient, who had a great improvement of visual perimetry and a decrease of α-SU levels but unmodified CT scan features. In our series of patients, octreotide was ineffective in reducing tumor mass. The efficacy of octreotide might rely on the presence of somatostatin receptors on adenoma-cell membranes. Therefore patients with functionless adenomas to be treated with octreotide might be identified with pituitary scintiscan using the recently available labeled111In-octreotide.

Original languageEnglish
Pages (from-to)149-155
Number of pages7
JournalHormone Research in Paediatrics
Volume40
Issue number4
DOIs
Publication statusPublished - 1993

Fingerprint

Octreotide
Pituitary Neoplasms
Therapeutics
Adenoma
Somatostatin Receptors
Visual Field Tests
Glucose Tolerance Test
Visual Fields
Insulin-Like Growth Factor I
Thyroid Gland
Cell Membrane
Insulin
Glucose
Serum

Keywords

  • GH
  • Glucose
  • IGF-I
  • Insulin
  • Pituitary adenomas
  • Somatostatin
  • α-Subunit

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. / Merola, Bartolomeo; Colao, Annamaria; Ferone, Diego; Selleri, Antonello; Di Sarno, Antonella; Marzullo, Paolo; Biondi, Bernadette; Spazinate, Renato; Rossi, Emanuela; Lombardi, Gaetano.

In: Hormone Research in Paediatrics, Vol. 40, No. 4, 1993, p. 149-155.

Research output: Contribution to journalArticle

Merola, B, Colao, A, Ferone, D, Selleri, A, Di Sarno, A, Marzullo, P, Biondi, B, Spazinate, R, Rossi, E & Lombardi, G 1993, 'Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas', Hormone Research in Paediatrics, vol. 40, no. 4, pp. 149-155. https://doi.org/10.1159/000183785
Merola, Bartolomeo ; Colao, Annamaria ; Ferone, Diego ; Selleri, Antonello ; Di Sarno, Antonella ; Marzullo, Paolo ; Biondi, Bernadette ; Spazinate, Renato ; Rossi, Emanuela ; Lombardi, Gaetano. / Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. In: Hormone Research in Paediatrics. 1993 ; Vol. 40, No. 4. pp. 149-155.
@article{010ebb6d77ab45edac8280488861db75,
title = "Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas",
abstract = "The effects of a chronic treatment with octreotide were evaluated in 19 patients affected with functionless pituitary adenomas. Octreotide caused a significant decrease of GH and IGF-I levels in all the patients and no significant change in thyroid, adrenal and gonadal function. In contrast, during the therapy, the glucose response to an oral glucose tolerance test considerably increased and was delayed, while the insulin response decreased and was delayed. Serum a-subunit (α-SU) was above normal in 10 of 16 patients in which this evaluation was performed: octreotide caused a significant decrease (p <0.01) of a-SU levels in 6 of these 10 patients. Octreotide did not induce any significant change in visual fields except in 1 patient, who had a great improvement of visual perimetry and a decrease of α-SU levels but unmodified CT scan features. In our series of patients, octreotide was ineffective in reducing tumor mass. The efficacy of octreotide might rely on the presence of somatostatin receptors on adenoma-cell membranes. Therefore patients with functionless adenomas to be treated with octreotide might be identified with pituitary scintiscan using the recently available labeled111In-octreotide.",
keywords = "GH, Glucose, IGF-I, Insulin, Pituitary adenomas, Somatostatin, α-Subunit",
author = "Bartolomeo Merola and Annamaria Colao and Diego Ferone and Antonello Selleri and {Di Sarno}, Antonella and Paolo Marzullo and Bernadette Biondi and Renato Spazinate and Emanuela Rossi and Gaetano Lombardi",
year = "1993",
doi = "10.1159/000183785",
language = "English",
volume = "40",
pages = "149--155",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas

AU - Merola, Bartolomeo

AU - Colao, Annamaria

AU - Ferone, Diego

AU - Selleri, Antonello

AU - Di Sarno, Antonella

AU - Marzullo, Paolo

AU - Biondi, Bernadette

AU - Spazinate, Renato

AU - Rossi, Emanuela

AU - Lombardi, Gaetano

PY - 1993

Y1 - 1993

N2 - The effects of a chronic treatment with octreotide were evaluated in 19 patients affected with functionless pituitary adenomas. Octreotide caused a significant decrease of GH and IGF-I levels in all the patients and no significant change in thyroid, adrenal and gonadal function. In contrast, during the therapy, the glucose response to an oral glucose tolerance test considerably increased and was delayed, while the insulin response decreased and was delayed. Serum a-subunit (α-SU) was above normal in 10 of 16 patients in which this evaluation was performed: octreotide caused a significant decrease (p <0.01) of a-SU levels in 6 of these 10 patients. Octreotide did not induce any significant change in visual fields except in 1 patient, who had a great improvement of visual perimetry and a decrease of α-SU levels but unmodified CT scan features. In our series of patients, octreotide was ineffective in reducing tumor mass. The efficacy of octreotide might rely on the presence of somatostatin receptors on adenoma-cell membranes. Therefore patients with functionless adenomas to be treated with octreotide might be identified with pituitary scintiscan using the recently available labeled111In-octreotide.

AB - The effects of a chronic treatment with octreotide were evaluated in 19 patients affected with functionless pituitary adenomas. Octreotide caused a significant decrease of GH and IGF-I levels in all the patients and no significant change in thyroid, adrenal and gonadal function. In contrast, during the therapy, the glucose response to an oral glucose tolerance test considerably increased and was delayed, while the insulin response decreased and was delayed. Serum a-subunit (α-SU) was above normal in 10 of 16 patients in which this evaluation was performed: octreotide caused a significant decrease (p <0.01) of a-SU levels in 6 of these 10 patients. Octreotide did not induce any significant change in visual fields except in 1 patient, who had a great improvement of visual perimetry and a decrease of α-SU levels but unmodified CT scan features. In our series of patients, octreotide was ineffective in reducing tumor mass. The efficacy of octreotide might rely on the presence of somatostatin receptors on adenoma-cell membranes. Therefore patients with functionless adenomas to be treated with octreotide might be identified with pituitary scintiscan using the recently available labeled111In-octreotide.

KW - GH

KW - Glucose

KW - IGF-I

KW - Insulin

KW - Pituitary adenomas

KW - Somatostatin

KW - α-Subunit

UR - http://www.scopus.com/inward/record.url?scp=0027771501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027771501&partnerID=8YFLogxK

U2 - 10.1159/000183785

DO - 10.1159/000183785

M3 - Article

C2 - 7507880

AN - SCOPUS:0027771501

VL - 40

SP - 149

EP - 155

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 4

ER -